A fixed duration combination of venetoclax with acalabrutinib, with or without obinutuzumab, was superior to standard ...

Sanofi reports positive Phase III results for its BTK inhibitor in treating immune thrombocytopenia, demonstrating faster ...

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of ...

BTIG initiated coverage of Nurix Therapeutics (NRIX) with a Buy rating and $35 price target Nurix is a protein degrader company whose lead ...

Sanofi has presented promising results from a phase 3 study of its investigational oral Bruton’s tyrosine kinase (BTK) ...

SAN DIEGO -- Treatment with an investigational oral inhibitor of Bruton's tyrosine kinase (BTK) was safe and boosted platelet ...

Eli Lilly (LLY) and Company announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent Bruton’s tyrosine ...

As reported by the South China Morning Post today, Everest Medicines (HKEX 1952.HK) is accelerating its journey to become a leading bi ...

Data from the Phase I/II TRANSCEND CLL 004 study evaluating the combination of Bristol Myers Squibb’s (BMS’s) Breyanzi ...

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...

New Delhi: Pharmaceutical major Glenmark Pharmaceuticals has got the go-ahead from the Subject Expert Committee (SEC) ...

Tolebrutinib is a small molecule commercialized by Sanofi, with a leading Phase III program in Secondary Progressive Multiple Sclerosis (SPMS).